Latest C-peptide Stories
LA JOLLA, Calif., June 16, 2011 /PRNewswire/ -- Cebix Incorporated announced today it is advancing the development of modified C-peptide for the treatment of complications of diabetes.
PERTH, Australia and LELYSTAD, The Netherlands, May 10, 2011 /PRNewswire/ -- Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.
WORCESTER, Mass. and TORONTO, May 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced publication of results of studies applicable to the early diagnosis, and possibly treatment of, Type 1 diabetes.
LELYSTAD, The Netherlands, April 4, 2011 /PRNewswire/ -- Pepscan Therapeutics, the Dutch biotech company focusing on protein mimicry for the discovery of therapeutics peptides and antibodies, announced today the appointment of Michiel Lodder as Chief Business Officer. Dr.
SAN MATEO, Calif., March 30, 2011 /PRNewswire/ -- Nile Therapeutics, Inc.
SAN MATEO, Calif., Feb. 28, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced plans to pursue a new indication in the field of heart failure.
QUÃ‰BEC CITY, Feb. 22 /PRNewswire/ - Aeterna Zentaris Inc.
CRANBURY, N.J., Feb. 18, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will host a conference call and webcast on February 24, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended December 31, 2010 financial results and plans for its programs under development.
NES-ZIONA, Israel, Jan. 18, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd.
WALTHAM, Massachusetts and LELYSTAD, The Netherlands, January 3, 2011 /PRNewswire/ -- Mercator Therapeutics, the first biopharmaceutical company to systematically use in vivo phage display technology to develop novel cancer drugs and Pepscan Therapeutics, a world leader in protein mimicry technologies for improved therapeutic peptides and anti-GPCR antibodies, today announced a multi-program research collaboration.
- A poem in which the author retracts something said in an earlier poem.